{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:26:21Z","timestamp":1784168781423,"version":"3.55.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0225112","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T18:24:41Z","timestamp":1577471081000},"page":"e0225112","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-258X","authenticated-orcid":true,"given":"Chen-Yu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"pone.0225112.ref001","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies","volume":"58","author":"SB Kaushik","year":"2019","journal-title":"Int J Dermatol"},{"key":"pone.0225112.ref002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan","volume":"39","author":"YT Cho","year":"2012","journal-title":"J Dermatol"},{"key":"pone.0225112.ref003","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"HY Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"pone.0225112.ref004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study","volume":"98","author":"HY Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"pone.0225112.ref005","first-page":"412","article-title":"A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects","volume":"151","author":"YC Tsai","year":"2016","journal-title":"G Ital di Dermatologia e Venereol"},{"key":"pone.0225112.ref006","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"KA Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"pone.0225112.ref007","first-page":"5591","article-title":"Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People\u2019s Republic of China","volume":"9","author":"CR Li","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"pone.0225112.ref008","first-page":"59","article-title":"Specific Detection of Tuberculosis Infection: An Interferon-Gamma-based Assay Using New Antigens","volume":"170","author":"T Mori","year":"2004","journal-title":"Am J Resp"},{"key":"pone.0225112.ref009","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/CDLI.6.4.606-609.1999","article-title":"Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis","volume":"6","author":"AD Lein","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"pone.0225112.ref010","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","article-title":"Predictive value of a whole blood IFN-\u03b3 assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis","volume":"177","author":"R Diel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0225112.ref011","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjd.13130","article-title":"Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy","volume":"171","author":"P Gisondi","year":"2014","journal-title":"Br J Dermatol"},{"key":"pone.0225112.ref012","unstructured":"Centers for Disease Control, Ministry of Health and Welfare, R.O.C.(Taiwan). 2015 Centers for disease control annual report. http:\/\/www.cdc.gov.tw\/uploads\/files\/201509\/0cc797c3-5252-477f-bd33-91b68c62238d.pdf."},{"key":"pone.0225112.ref013","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"pone.0225112.ref014","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","volume":"48","author":"BIOBADASER Group","year":"2003","journal-title":"Arthritis Rheum"},{"key":"pone.0225112.ref015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor","volume":"39","author":"AK Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"pone.0225112.ref016","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"T Bongartz","year":"2006","journal-title":"J Am Med Assoc"},{"key":"pone.0225112.ref017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.06.004","article-title":"To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis","volume":"73","author":"CS Ahn","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: A comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"RK Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"pone.0225112.ref019","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","article-title":"Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy","volume":"59","author":"DY Chen","year":"2008","journal-title":"Arthritis Care Res"},{"key":"pone.0225112.ref020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/kem064","article-title":"Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF- agents: the Newcastle (UK) experience","volume":"46","author":"A Pratt","year":"2007","journal-title":"Rheumatology"},{"key":"pone.0225112.ref021","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-Endemic population","volume":"35","author":"D Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"pone.0225112.ref022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon \u03b3 assay","volume":"67","author":"G Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"pone.0225112.ref023","article-title":"Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study","author":"V Aydin","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"pone.0225112.ref024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3343\/kjlm.2011.31.4.271","article-title":"Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents","volume":"31","author":"KH Kim","year":"2011","journal-title":"Korean J Lab Med"},{"key":"pone.0225112.ref025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1468-3083.2011.04220.x","article-title":"Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: A prospective, observational study","volume":"26","author":"S Garcovich","year":"2012","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"pone.0225112.ref026","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"C Hatzara","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"pone.0225112.ref027","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jinf.2012.10.017","article-title":"Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment","volume":"66","author":"F Bartalesi","year":"2013","journal-title":"J Infect"},{"key":"pone.0225112.ref028","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/bjd.12544","article-title":"Interferon-\u03b3 release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: In vivo and in vitro analysis","volume":"169","author":"I Sauzullo","year":"2013","journal-title":"Br J Dermatol"},{"key":"pone.0225112.ref029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2018.03.025","article-title":"Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: A retrospective cohort study identifying an important practice gap","volume":"79","author":"J Chung","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.dsi.2014.12.005","article-title":"Serial QuantiFERON-TB Gold In-Tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy","volume":"33","author":"CY Cheng","year":"2015","journal-title":"Dermatologica Sin"},{"key":"pone.0225112.ref031","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"A Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref032","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1346-8138.12239","article-title":"Japanese guidance for use of biologics for psoriasis (the 2013 version)","volume":"40","author":"M Ohtsuki","year":"2013","journal-title":"J Dermatol"},{"key":"pone.0225112.ref033","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014Update 2015\u2014Short version\u2014EDF in cooperation with EADV and IPC","volume":"29","author":"A Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"pone.0225112.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184178","article-title":"Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab","volume":"12","author":"CY Hsiao","year":"2017","journal-title":"PLoS One"},{"key":"pone.0225112.ref035","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","volume":"168","author":"TF Tsai","year":"2013","journal-title":"Br J Dermatol"},{"key":"pone.0225112.ref036","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2012.2958","article-title":"Peripheral Lymph Node Recurrence of Tuberculosis After Ustekinumab Treatment","volume":"148","author":"AI S\u00e1nchez-Moya","year":"2012","journal-title":"Arch Dermatol"},{"key":"pone.0225112.ref037","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1684\/ejd.2014.2386","article-title":"Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, Despite isoniazid chemoprophylaxis","volume":"24","author":"E Errichetti","year":"2014","journal-title":"Eur J Dermatology"},{"key":"pone.0225112.ref038","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections","volume":"80","author":"SB Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref039","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"PC van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref040","unstructured":"Riedl E, Winkler S, Xu W, Agada N, Lebwohl M. P1827 No reactivation of tuberculosis in psoriasis patients with latent tuberculosis infection while on ixekizumab treatment: a report from 11 clinical studies. 27th Eur Acad Dermatology Venereol Congr 2018, Paris. 2018."},{"key":"pone.0225112.ref041","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"M Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"pone.0225112.ref042","doi-asserted-by":"crossref","first-page":"36923","DOI":"10.1038\/srep36923","article-title":"Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNF\u03b1 neutralization","volume":"6","author":"N Segueni","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0225112.ref043","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/1346-8138.13900","article-title":"Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study","volume":"44","author":"NL Wu","year":"2017","journal-title":"J Dermatol"},{"key":"pone.0225112.ref044","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.dsi.2012.08.002","article-title":"T helper type 17 in psoriasis: From basic immunology to clinical practice","volume":"30","author":"HY Chiu","year":"2012","journal-title":"Dermatologica Sin"},{"key":"pone.0225112.ref045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study","volume":"98","author":"HY Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"pone.0225112.ref046","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1111\/ijd.13346","article-title":"The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis","volume":"55","author":"HY Chiu","year":"2016","journal-title":"Int J Dermatol"},{"key":"pone.0225112.ref047","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2016.02.1168","article-title":"The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study","volume":"75","author":"HY Chiu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref048","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"M Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"pone.0225112.ref049","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","article-title":"IL-17 and Th17 cells in tuberculosis","volume":"21","author":"CooperAM TorradoE","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"pone.0225112.ref050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00294","article-title":"Interactions between type 1 interferons and the Th17 response in tuberculosis: Lessons learned from autoimmune diseases","volume":"8","author":"BC Mourik","year":"2017","journal-title":"Front Immunol"},{"key":"pone.0225112.ref051","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0018-2016","article-title":"Cytokines and Chemokines in Mycobacterium tuberculosis Infection","volume":"4","author":"R Domingo-Gonzalez","year":"2016","journal-title":"Microbiol Spectr"},{"key":"pone.0225112.ref052","doi-asserted-by":"crossref","first-page":"741","DOI":"10.12688\/f1000research.10862.1","article-title":"Yin and yang of interleukin-17 in host immunity to infection","volume":"6","author":"S Das","year":"2017","journal-title":"F1000Research"},{"key":"pone.0225112.ref053","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cyto.2017.05.015","article-title":"The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers","volume":"97","author":"RT Robinson","year":"2017","journal-title":"Cytokine"},{"key":"pone.0225112.ref054","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00498","article-title":"IL-17A promotes intracellular growth of Mycobacterium by inhibiting apoptosis of infected macrophages","volume":"6","author":"A Cruz","year":"2015","journal-title":"Front Immunol"},{"key":"pone.0225112.ref055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"A Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"pone.0225112.ref056","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris\u2014Update Apremilast and Secukinumab\u2014EDF in cooperation with EADV and IPC","volume":"31","author":"A Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"pone.0225112.ref057","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1378\/chest.13-1232","article-title":"Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study","volume":"145","author":"JL Johnson","year":"2014","journal-title":"Chest"},{"key":"pone.0225112.ref058","first-page":"224","article-title":"Severe isoniazid associated liver injuries among persons being treated for latent tuberculosis infection\u2014United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0225112.ref059","first-page":"780","article-title":"How much isoniazid is needed for prophylaxis?","volume":"101","author":"GW Comstock","year":"1970","journal-title":"Am Rev Respir Dis"},{"key":"pone.0225112.ref060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7883\/yoken.JJID.2009.300","article-title":"False negative results of QuantiFERON TB-2G test in patients with active tuberculosis","volume":"62","author":"Y Kobashi","year":"2009","journal-title":"Jpn J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:20:50Z","timestamp":1722237650000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225112"}},"subtitle":[],"editor":[{"given":"Katalin Andrea","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0225112","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]}}}